INFI


3 “Strong Buy” Penny Stocks With Triple-Digit Upside Potential

Are penny stocks a must-have or a must-avoid? Well, that depends on who you ask.

Company Update (NASDAQ:INFI): Infinity Pharmaceuticals Inc. to Present Phase 1b IPI-549 Data at the 2017 Society for Immunotherapy of Cancer Annual Meeting

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) announced that clinical data from its IPI-549 Phase 1/1b study was selected as a late-breaking abstract and will be presented on …

Company Update (NASDAQ:INFI): Infinity Pharmaceuticals Inc. Presents Initial Clinical And New Preclinical Data On IPI-549 At Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) announced initial clinical and new preclinical data for IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma.

Wedbush Reiterates Neutral On Infinity Pharma As Duvelisib Phase 2a Misses Primary Endpoint

In a research report issued today, Wedbush analyst David Nierengarten reiterated a Neutral rating on Infinity Pharma (NASDAQ:INFI) with a $15 price target, …

William Blair Assigns Outperform On Infinity Pharmaceuticals Shares, $18 PT

In a research report issued today, William Blair analyst Y Katherine Xu assigned an Outperform rating on Infinity Pharmaceuticals (NASDAQ:INFI) with a price target …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts